Call us:

Neuroproteomics Research Solutions

Nearly 1 billion people suffer from mental health problems worldwide. Especially in low- and middle-income countries, there are a high prevalence of mental illness, neurodegenerative diseases, and substance abuse problems. Moreover, over 75% of patients are not under timely and effective treatment. WHO has repeatedly called for a massive increase in investment in mental health.

Because proteins ultimately mediate all brain functions, MS-based proteomics has become a powerful and versatile toolset for neuroproteomics, which can study proteins and their functions in an unbiased manner. According to incomplete statistics, a total of 2,253 articles related to proteomics in the field of neurological and mental diseases have been published (302 articles published in 2020).

Proteomics technology combined with biological and phenotypic experiments to reveal autism risk factors, translational regulation systematically, and molecular regulatory processes, etc., has deepened our understanding of autism pathogenesis. Moreover, it provides a feasible approach to overcome the heterogeneity of autism and new research ideas for autism drug development. Furthermore, large-scale proteomics and phosphoproteomics analyses of brain tissue samples from Alzheimer's disease (AD) patients can characterize the molecular networks associated with the progressive stages of AD, and obtain differential proteins involved in the relevant pathways to screen for new candidates biomarkers. These findings have led to continuous advances in basic and clinical research, allowing early diagnosis and precise treatment of neurological diseases to be gradually applied in clinical care.

Our Neuroproteomics Proteomics Services

Creative Proteomics provides proteomics services based on DIA MS and 4D technologies, enabling large-scale proteomic or phosphoproteomic analysis of brain tissue or cerebrospinal fluid to reveal the pathogenic mechanism of neurodegenerative diseases and discover new biomarkers for diagnosis, treatment, and prognosis. Our targeted proteomics platform can also be used for qualitative and quantitative analysis of specific proteins according to your needs.

Neurological Disease Research

Our proteomics solutions are suitable for a wide range of therapeutic areas including but not limited below:
Alzheimer's disease
Parkinson's disease




High accuracy: QC CV as low as 25% for large projects
High throughput, 1000-2600 proteins can be quantified at once
Quantitatively identify nearly all detectable molecules, covering low abundance proteins/peptides
High repetition rate: repeatability increased by 30% and up to 90%
Complete and comprehensive sample information storage in the first analysis
Standard and advanced data analysis

Sample Requirements

Proteins can be extracted from any biological source, such as whole tissues, cells, and body fluids. Creative Proteomics has developed an extraction method to obtain high-quality proteins from FFPE samples after extensive literature research and R&D testing.

Sample TypeProtein# of CellsCSF(fresh frozen)Fresh frozenFFPE slices
Quantify100 ug1×107 cells500 uL1 mg2×5 μm FFPE slices (each 50-100mm2)



  1. FabianHosp13 et al. A Primer on Concepts and Applications of Proteomics in Neuroscience. Neuron Volume  96 3, 1 558-571 (2017).
* For Research Use Only. Not for use in the treatment or diagnosis of disease.

Online Inquiry


Specializing in proteomics, Creative Proteomics offers cutting-edge protein analysis services. Our distinctive approach revolves around harnessing the power of DIA technology, enabling us to deliver precise and comprehensive insights that drive advancements in research and industry.

  • USA
  • Tel:
  • Fax:
  • Email:
  • Germany
Copyright © 2024 Creative Proteomics. All rights reserved.